You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

Anticoagulation

Idarucizumab for Dabigatran Reversal

20 Sep, 17 | by lfountain

The first direct oral anticoagulant (DOAC) was approved nearly a decade ago, yet there remains apprehension in transitioning to wide-spread use despite demonstrated efficacy and ease of use. One limitation is the absence of a reversal agent for patients on DOACs who develop significant bleeding or require emergent surgery. Idarucizumab is a humanized monoclonal antibody fragment which binds dabigatran and rapidly reverses anticoagulant activity.

more…

Latest from Heart

Latest from Heart

Cardiology Masterclasses

Cardiology Masterclasses